Skip to content
Tanzeum, Eperzan(albiglutide)
Eperzan, Tanzeum (albiglutide) is a protein pharmaceutical. Albiglutide was first approved as Eperzan on 2014-03-20. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. It is known to target glucagon-like peptide 1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Albiglutide
Tradename
Proper name
Company
Number
Date
Products
TanzeumalbiglutideGSKN-125431 DISCN2014-04-15
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ04: Albiglutide
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11105143—32
Diabetes mellitusD003920EFO_0000400E08-E13——12—3
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
Heart failureD006333EFO_0003144I50—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALBIGLUTIDE
INNalbiglutide
Description
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death. GSK has announced that it intends to withdraw the drug from the worldwide market by July 2018 for economic reasons.
Classification
Protein
Drug classpeptides: glucagon-like peptide (GLP) analogs
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID782500-75-8
RxCUI1534763
ChEMBL IDCHEMBL2107841
ChEBI ID—
PubChem CID—
DrugBankDB09043
UNII ID5E7U48495E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP1R
Gene synonyms
NCBI Gene ID
2740
Protein name
glucagon-like peptide 1 receptor
Protein synonyms
GLP-1 receptor, GLP1 receptor, seven transmembrane helix receptor
Uniprot ID
Q99669
Mouse ortholog
Glp1r (14652)
glucagon-like peptide 1 receptor (Q1JQR8)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,461 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
8,645 adverse events reported
View more details